Browse Studies About FAQ

Sign in Get started

Match. Apply. Get paid. The simplest way to participate in paid clinical research.

Product

Browse Studies How it Works Verification Arctuva Pro For Sponsors

Company

About Contact FAQ

Legal

Privacy Terms of Service Security Accessibility Transparency Report

© 2026 Arctuva, Inc. All rights reserved.

Compensation is for time and inconvenience, not income.

Browse Studies — Arctuva | Arctuva

Browse studies

Find your next paid study

1 recruiting study matching your filters

Newest first Highest paying

Filters

Condition

Location

Phase

Min compensation ($)

Max compensation ($)

A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma

Purpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after ra…

High-risk Muscle Invasive Urothelial Carcinoma

~$10 – $7,500

AstraZenecaNCT07720284